Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Page Banner for mobile screens

A Sneak Peek into the Top 10 Abstracts on PD-(L)1 Inhibitors at ASCO 2024

PD-(L)1 Inhibitors Top Abstracts | ASCO 2024

Clinical trials testing PD-(L)1 inhibitors have tripled in the recent years, with more than 4,400 clinical trials (more than 3,600 are ongoing). This growth has been led by combination trials; ~90% of the new trials started in 2020 are combination strategies. We all know the success story of Keytruda, which has emerged as a dominant player in the market, securing approvals across 20+ indications. Interestingly, the position of leading brands in the current competitive landscape largely mirrors the order of their market entry. KEYTRUDA and OPDIVO continue to command the checkpoint inhibitor market due to their early entry and established track record.

During ASCO 2024, Top pharmaceutical companies such as AstraZeneca, Merck, Bristol Myers Squibb, BeiGene, AkesoBio, Hengrui, and Qilu Pharma are ready to present initial, updated and final results. The upcoming session is highly anticipated for its unveiling of primary results from the Phase III CheckMate -9DW study, hoping to offer a potential treatment option to improve outcomes compared to well-established tyrosine kinase inhibitor for hepatocellular cancer. Results from bi-specific PD-1 inhibitors such as Acasunlimab (PD-1 X 4-1BB) and IBI363 (PD-1 and IL-2) will also be of much interest. Additionally, data from Chinese pharma companies is also much awaited.

In this context, Delveinsight has meticulously compiled a list of the most potential 10 abstracts.

Company

Drug

Trial ID / Acronym

Phase

Abstract ID

Abstract Title

Nivolumab

NCT04025879/

CheckMate 77T

III

Oral Abstract Session - LBA8007

Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.

Nivolumab

NCT04039607/

CheckMate 9DW

III

Oral Abstract 

- LBA4008

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

Durvalumab

NCT03778957/

EMERALD-1

III

Poster Session- 102,

Abstract- 4122

Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.

Tislelizumab

NCT03783442/

RATIONALE-306

III

Poster Session- 12,

Abstract- 4032

Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.

Hengrui Pharma Business Development Team | LinkedIn

Camrelizumab

NCT03764293

III

Poster Session- 90,

Abstract- 4110

Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.

Iparomlimab/

tuvonralimab

NCT05576272 (DUBHE-N-302)

II/III

Poster Session- 329,

Abstract- 6026

Safety and efficacy of iparomlimab and tuvonralimab in combination with gemcitabine and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 trial (DUBHE-N-302).

Acasunlimab

NCT05117242

II

Poster Session- 12, Abstract- 2533

Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.

Pembrolizumab/Favezelimab

NCT03598608

I/II

Poster Session- 39, Abstract- 7056

A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.

Cadonilimab

NCT04982276

I/II

Rapid Oral

Abstract- 4012

Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial.

IBI363

NCT05460767

I

Poster Session- 256, Abstract- 3593

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study.

 

Tags:

Executive Summary

During ASCO 2024, Top pharmaceutical companies such as AstraZeneca, Merck, Bristol Myers Squibb, BeiGene, AkesoBio, Hengrui, and Qilu Pharma are ready to present initial, updated and final results.

Recent Articles